Research Study Findings from National Cancer Institute (NCI) Update Understanding of Immunoconjugates (Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers)

  • William Figg

Press/Media

Period3 May 2024

Media coverage

1

Media coverage

  • TitleResearch Study Findings from National Cancer Institute (NCI) Update Understanding of Immunoconjugates (Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers)
    Media name/outletNewsRx Cardiovascular Daily
    Country/TerritoryUnited States
    Date3/05/24
    PersonsWilliam Figg
View all 1
View less

Related content